/ Key word(s): Half Year Results
Allschwil, Switzerland, August 31, 2022
Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET.
To participate, please use the following numbers:
France: +33 (0)1 70 730 3 39
Germany: +49 (0)69 22222 5197
Italy: +39 0200638217
Switzerland: +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States +1 646-828-8073
Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis H1 2022 Financial Results and Business Update” – and the following confirmation code: 7688870.
The presentation will also be available via webcast:
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.
In addition, management will participate at the following events in September:
Stephan Wehselau, COO, will give a company presentation on September 6th at 10:45 AM CET and will also meet with investors.
Dr. Wager will give a company presentation and meet with investors.
September 28-29, 2022, Boston, U.S. (in-person) & October 4-5, 2022 (virtual)
Dr. Wager will participate in this partnering event. Anyone interested in speaking with the company is invited to request a meeting via the PARTNERINGONE® platform.
For further information please contact:
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1431709|
|End of News||EQS News Service|
1431709 31.08.2022 CET/CEST